HCPCS Level II

HCPCS Level II 2022 code changes

Every HCPCS Level II code whose CMS add date or termination date falls in 2022, grouped by effective date. Each code's own page carries its full record.

214

Added

Deleted

For HCPCS Level II, MedCoder records each code's CMS add date and termination date from the alpha-numeric file. A deletion is listed on the first day the code is no longer valid (the day after its CMS termination date). Description revisions between quarterly files are not recorded as changes.

Added effective January 1, 2022 (124)

A2001 — Innovamatrix ac, per square centimeter (add-on, list separately in addition to primary procedure)
A2002 — Mirragen advanced wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)
A2004 — Xcellistem, 1 mg
A2005 — Microlyte matrix, per square centimeter (add-on, list separately in addition to primary procedure)
A2006 — Novosorb synpath dermal matrix, per square centimeter (add-on, list separately in addition to primary procedure)
A2007 — Restrata, per square centimeter (add-on, list separately in addition to primary procedure)
A2008 — Theragenesis, per square centimeter (add-on, list separately in addition to primary procedure)
A2009 — Symphony, per square centimeter (add-on, list separately in addition to primary procedure)
A2010 — Apis, per square centimeter (add-on, list separately in addition to primary procedure)
A4436 — Irrigation supply; sleeve, reusable, per month
A4437 — Irrigation supply; sleeve, disposable, per month
A9595 — Piflufolastat f 18 (pylarify), diagnostic, 1 millicurie
C1832 — Autograft suspension, including cell processing and application, and all system components
C1833 — Monitor, cardiac, including intracardiac lead and all system components (implantable)
C9085 — Injection, avalglucosidase alfa-ngpt, 4 mg
C9086 — Injection, anifrolumab-fnia, 1 mg
C9087 — Injection, cyclophosphamide, (auromedics), 10 mg
C9088 — Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
C9089 — Bupivacaine, collagen-matrix implant, 1 mg
E1629 — Tablo hemodialysis system for the billable dialysis service
G0028 — Documentation of medical reason(s) for not screening for tobacco use (e.g., limited life expectancy, other medical reason)
G0029 — Tobacco screening not performed or tobacco cessation intervention not provided during the measurement period or in the six months prior to the measurement period
G0030 — Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user
G0031 — Palliative care services given to patient any time during the measurement period
G0032 — Two or more antipsychotic prescriptions ordered for patients who had a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder on or between january 1 of the year prior to the measurement period and the index prescription start date (ipsd) for antipsychotics
G0033 — Two or more benzodiazepine prescriptions ordered for patients who had a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between january 1 of the year prior to the measurement period and the ipsd for benzodiazepines
G0034 — Patients receiving palliative care during the measurement period
G0035 — Patient has any emergency department encounter during the performance period with place of service indicator 23
G0036 — Patient or care partner decline assessment
G0037 — On date of encounter, patient is not able to participate in assessment or screening, including non-verbal patients, delirious, severely aphasic, severely developmentally delayed, severe visual or hearing impairment and for those patients, no knowledgeable informant available
G0038 — Clinician determines patient does not require referral
G0039 — Patient not referred, reason not otherwise specified
G0040 — Patient already receiving physical/occupational/speech/recreational therapy during the measurement period
G0041 — Patient and/or care partner decline referral
G0042 — Referral to physical, occupational, speech, or recreational therapy
G0043 — Patients with mechanical prosthetic heart valve
G0044 — Patients with moderate or severe mitral stenosis
G0045 — Clinical follow-up and mrs score assessed at 90 days following endovascular stroke intervention
G0046 — Clinical follow-up and mrs score not assessed at 90 days following endovascular stroke intervention
G0047 — Pediatric patient with minor blunt head trauma and pecarn prediction criteria are not assessed
G0048 — Patients who receive palliative care services any time during the intake period through the end of the measurement year
G0049 — With maintenance hemodialysis (in-center and home hd) for the complete reporting month
G0050 — Patients with a catheter that have limited life expectancy
G0051 — Patients under hospice care in the current reporting month
G0052 — Patients on peritoneal dialysis for any portion of the reporting month
G0053 — Advancing rheumatology patient care mips value pathways
G0054 — Coordinating stroke care to promote prevention and cultivate positive outcomes mips value pathways
G0055 — Advancing care for heart disease mips value pathways
G0056 — Optimizing chronic disease management mips value pathways
G0057 — Proposed adopting best practices and promoting patient safety within emergency medicine mips value pathways
G0058 — Improving care for lower extremity joint repair mips value pathways
G0059 — Patient safety and support of positive experiences with anesthesia mips value pathways
G0060 — Allergy/immunology mips specialty set
G0061 — Anesthesiology mips specialty set
G0062 — Audiology mips specialty set
G0063 — Cardiology mips specialty set
G0064 — Certified nurse midwife mips specialty set
G0065 — Chiropractic medicine mips specialty set
G0066 — Clinical social work mips specialty set
G0067 — Dentistry mips specialty set
G1024 — Clinical decision support mechanism radrite, as defined by the medicare appropriate use criteria program
G1025 — Patient-months where there are more than one medicare capitated payment (mcp) provider listed for the month
G1026 — The number of adult patient-months in the denominator who were on maintenance hemodialysis using a catheter continuously for three months or longer under the care of the same practitioner or group partner as of the last hemodialysis session of the reporting month
G1027 — The number of adult patient-months in the denominator who were on maintenance hemodialysis under the care of the same practitioner or group partner as of the last hemodialysis session of the reporting month using a catheter continuously for less than three months
G1028 — Take-home supply of nasal naloxone; 2-pack of 8mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
G4000 — Dermatology mips specialty set
G4001 — Diagnostic radiology mips specialty set
G4002 — Electrophysiology cardiac specialist mips specialty set
G4003 — Emergency medicine mips specialty set
G4004 — Endocrinology mips specialty set
G4005 — Family medicine mips specialty set
G4006 — Gastro-enterology mips specialty set
G4007 — General surgery mips specialty set
G4008 — Geriatrics mips specialty set
G4009 — Hospitalists mips specialty set
G4010 — Infectious disease mips specialty set
G4011 — Internal medicine mips specialty set
G4012 — Interventional radiology mips specialty set
G4013 — Mental/behavioral and psychiatry mips specialty set
G4014 — Nephrology mips specialty set
G4015 — Neurology mips specialty set
G4016 — Neurosurgical mips specialty set
G4017 — Nutrition/dietician mips specialty set
G4018 — Obstetrics/gynecology mips specialty set
G4019 — Oncology/hematology mips specialty set
G4020 — Ophthalmology/optometry mips specialty set
G4021 — Orthopedic surgery mips specialty set
G4022 — Otolaryngology mips specialty set
G4023 — Pathology mips specialty set
G4024 — Pediatrics mips specialty set
G4025 — Physical medicine mips specialty set
G4026 — Physical therapy/occupational therapy mips specialty set
G4027 — Plastic surgery mips specialty set
G4028 — Podiatry mips specialty set
G4029 — Preventive medicine mips specialty set
G4030 — Pulmonology mips specialty set
G4031 — Radiation oncology mips specialty set
G4032 — Rheumatology mips specialty set
G4033 — Skilled nursing facility mips specialty set
G4034 — Speech language pathology mips specialty set
G4035 — Thoracic surgery mips specialty set
G4036 — Urgent care mips specialty set
G4037 — Urology mips specialty set
G4038 — Vascular surgery mips specialty set
G9988 — Palliative care services provided to patient any time during the measurement period
G9989 — Documentation of medical reason(s) for not administering pneumococcal vaccine (e.g., adverse reaction to vaccine)
G9990 — Patient did not receive any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period
G9991 — Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period
G9992 — Palliative care services used by patient any time during the measurement period
G9993 — Patient was provided palliative care services any time during the measurement period
G9994 — Patient is using palliative care services any time during the measurement period
G9995 — Patients who use palliative care services any time during the measurement period
G9996 — Documentation stating the patient has received or is currently receiving palliative or hospice care
G9997 — Documentation of patient pregnancy anytime during the measurement period prior to and including the current encounter
G9998 — Documentation of medical reason(s) for an interval of less than 3 years since the last colonoscopy (e.g., last colonoscopy incomplete, last colonoscopy had inadequate prep, piecemeal removal of adenomas, or sessile serrated polyps >= 20 mm in size, last colonoscopy found greater than 10 adenomas, lower gastrointestinal bleeding, or patient at high risk for colon cancer due to underlying medical history ([i.e. crohn's disease, ulcerative colitis, personal or family history of colon cancer, hereditary colorectal cancer syndromes])
G9999 — Documentation of system reason(s) for an interval of less than 3 years since the last colonoscopy (e.g., unable to locate previous colonoscopy report, patient cannot provide precise date or details from previous colonoscopy, previous colonoscopy report was incomplete)
J0172 — Injection, aducanumab-avwa, 2 mg
J1952 — Leuprolide injectable, camcevi, 1 mg
J2506 — Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
J9021 — Injection, asparaginase, recombinant, (rylaze), 0.1 mg
J9061 — Injection, amivantamab-vmjw, 2 mg
J9272 — Injection, dostarlimab-gxly, 10 mg
Q2055 — Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q4199 — Cygnus matrix, per square centimeter (add-on, list separately in addition to primary procedure)

Deleted effective January 1, 2022 (49)

A4397 — Irrigation supply; sleeve, each
C9081 — Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
C9082 — Injection, dostarlimab-gxly, 100 mg
C9083 — Injection, amivantamab-vmjw, 10 mg
C9752 — Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum
C9753 — Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)
G0424 — Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day
G2064 — Comprehensive care management services for a single high-risk disease, e.g., principal care management, at least 30 minutes of physician or other qualified health care professional time per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been the cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities
G2065 — Comprehensive care management for a single high-risk disease services, e.g. principal care management, at least 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities
G8422 — Bmi not documented, documentation the patient is not eligible for bmi calculation
G8925 — Spirometry test results demonstrate fev1 >= 60% fev1/fvc >= 70%, predicted or patient does not have copd symptoms
G8926 — Spirometry test not performed or documented, reason not given
G8938 — Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible
G9267 — Documentation of patient with one or more complications or mortality within 30 days
G9268 — Documentation of patient with one or more complications within 90 days
G9269 — Documentation of patient without one or more complications and without mortality within 30 days
G9270 — Documentation of patient without one or more complications within 90 days
G9348 — Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons
G9349 — Ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis
G9350 — Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis
G9399 — Documentation in the patient record of a discussion between the physician/clinician and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward the outcome of the treatment
G9400 — Documentation of medical or patient reason(s) for not discussing treatment options; medical reasons: patient is not a candidate for treatment due to advanced physical or mental health comorbidity (including active substance use); currently receiving antiviral treatment; successful antiviral treatment (with sustained virologic response) prior to reporting period; other documented medical reasons; patient reasons: patient unable or unwilling to participate in the discussion or other patient reasons
G9401 — No documentation in the patient record of a discussion between the physician or other qualified healthcare professional and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward treatment
G9448 — Patients who were born in the years 1945 to 1965
G9449 — History of receiving blood transfusions prior to 1992
G9450 — History of injection drug use
G9561 — Patients prescribed opiates for longer than six weeks
G9562 — Patients who had a follow-up evaluation conducted at least every three months during opioid therapy
G9563 — Patients who did not have a follow-up evaluation conducted at least every three months during opioid therapy
G9577 — Patients prescribed opiates for longer than six weeks
G9578 — Documentation of signed opioid treatment agreement at least once during opioid therapy
G9579 — No documentation of signed an opioid treatment agreement at least once during opioid therapy
G9583 — Patients prescribed opiates for longer than six weeks
G9584 — Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy
G9585 — Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not interviewed at least once during opioid therapy
G9634 — Health-related quality of life assessed with tool during at least two visits and quality of life score remained the same or improved
G9635 — Health-related quality of life not assessed with tool for documented reason(s) (e.g., patient has a cognitive or neuropsychiatric impairment that impairs his/her ability to complete the hrqol survey, patient has the inability to read and/or write in order to complete the hrqol questionnaire)
G9636 — Health-related quality of life not assessed with tool during at least two visits or quality of life score declined
G9639 — Major amputation or open surgical bypass not required within 48 hours of the index endovascular lower extremity revascularization procedure
G9640 — Documentation of planned hybrid or staged procedure
G9641 — Major amputation or open surgical bypass required within 48 hours of the index endovascular lower extremity revascularization procedure
G9647 — Patients in whom mrs score could not be obtained at 90 day follow-up
G9666 — Patient's highest fasting or direct ldl-c laboratory test result in the measurement period or two years prior to the beginning of the measurement period is 70-189 mg/dl
G9783 — Documentation of patients with diabetes who have a most recent fasting or direct ldl- c laboratory test result < 70 mg/dl and are not taking statin therapy
J2505 — Injection, pegfilgrastim, 6 mg
M1022 — Patients who were in hospice at any time during the performance period
M1025 — Patients who were in hospice at any time during the performance period
M1026 — Patients who were in hospice at any time during the performance period
M1031 — Patients with no clinical indications for imaging of the head

Added effective February 11, 2022 (3)

M0222 — Intravenous injection, bebtelovimab, includes injection and post administration monitoring
M0223 — Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
Q0222 — Injection, bebtelovimab, 175 mg

Added effective February 24, 2022 (1)

Q0221 — Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg

Deleted effective February 28, 2022 (1)

M1145 — Most favored nation (mfn) model drug add-on amount, per dose, (do not bill with line items that have the jw modifier)

Added effective April 1, 2022 (36)

A2011 — Supra sdrm, per square centimeter (add-on, list separately in addition to primary procedure)
A2012 — Suprathel, per square centimeter (add-on, list separately in addition to primary procedure)
A2013 — Innovamatrix fs, per square centimeter (add-on, list separately in addition to primary procedure)
A4100 — Non-sheet form skin substitute, fda cleared as a device, not otherwise specified (list in addition to primary procedure)
A4238 — Supply allowance for adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service
A9291 — Prescription digital cognitive and/or behavioral therapy, fda cleared, per course of treatment
C9090 — Injection, plasminogen, human-tvmh, 1 mg
C9091 — Injection, sirolimus protein-bound particles, 1 mg
C9092 — Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg
C9093 — Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg
C9781 — Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed
C9782 — Blinded procedure for new york heart association (nyha) class ii or iii heart failure, or canadian cardiovascular society (ccs) class iii or iv chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells (e.g., mononuclear) or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory services, and all imaging with or without guidance (e.g., transthoracic echocardiography, ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) study
C9783 — Blinded procedure for transcatheter implantation of coronary sinus reduction device or placebo control, including vascular access and closure, right heart catheterization, venous and coronary sinus angiography, imaging guidance and supervision and interpretation when performed in an approved investigational device exemption (ide) study
E2102 — Adjunctive, non-implanted continuous glucose monitor or receiver
H2038 — Skills training and development, per diem
J0219 — Injection, avalglucosidase alfa-ngpt, 4 mg
J0491 — Injection, anifrolumab-fnia, 1 mg
J0879 — Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)
J9071 — Injection, cyclophosphamide (auromedics), 5 mg
J9273 — Injection, tisotumab vedotin-tftv, 1 mg
J9359 — Injection, loncastuximab tesirine-lpyl, 0.075 mg
K1028 — Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application
K1029 — Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply
K1030 — External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only
K1031 — Non-pneumatic compression controller without calibrated gradient pressure
K1032 — Non-pneumatic sequential compression garment, full leg
K1033 — Non-pneumatic sequential compression garment, half leg
Q4224 — Human health factor 10 amniotic patch (hhf10-p), per square centimeter (add-on, list separately in addition to primary procedure)
Q4225 — Amniobind or dermabind tl, per square centimeter (add-on, list separately in addition to primary procedure)
Q4256 — Mlg-complete, per square centimeter (add-on, list separately in addition to primary procedure)
Q4257 — Relese, per square centimeter (add-on, list separately in addition to primary procedure)
Q4258 — Enverse, per square centimeter (add-on, list separately in addition to primary procedure)
Q5124 — Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
T2050 — Financial management, self-directed, waiver; per diem
T2051 — Supports brokerage, self-directed, waiver; per diem
V2525 — Contact lens, hydrophilic, dual focus, per lens

Deleted effective April 1, 2022 (5)

C9084 — Injection, loncastuximab tesirine-lpyl, 0.1 mg
C9085 — Injection, avalglucosidase alfa-ngpt, 4 mg
C9086 — Injection, anifrolumab-fnia, 1 mg
C9087 — Injection, cyclophosphamide, (auromedics), 10 mg
G1009 — Clinical decision support mechanism sage health management solutions, as defined by the medicare appropriate use criteria program

Added effective April 4, 2022 (1)

K1034 — Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count

Added effective May 11, 2022 (6)

G0310 — Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time (this code is used for medicaid billing purposes)
G0311 — Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time (this code is used for medicaid billing purposes)
G0312 — Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time (this code is used for medicaid billing purposes)
G0313 — Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time (this code is used for medicaid billing purposes)
G0314 — Immunization counseling by a physician or other qualified health care professional for covid-19, ages under 21, 16-30 mins time (this code is used for the medicaid early and periodic screening, diagnostic, and treatment benefit (epsdt)
G0315 — Immunization counseling by a physician or other qualified health care professional for covid-19, ages under 21, 5-15 mins time (this code is used for the medicaid early and periodic screening, diagnostic, and treatment benefit (epsdt)

Added effective July 1, 2022 (21)

A9596 — Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie
A9601 — Flortaucipir f 18 injection, diagnostic, 1 millicurie
C9094 — Inj, sutimlimab-jome, 10 mg
C9095 — Inj, tebentafusp-tebn, 1 mcg
C9096 — Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
C9097 — Inj, faricimab-svoa, 0.1 mg
C9098 — Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
G0308 — Creation of subcutaneous pocket with insertion of 180 day implantable interstitial glucose sensor, including system activation and patient training
G0309 — Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new 180 day implantable sensor, including system activation
J0739 — Injection, cabotegravir, 1mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J1306 — Injection, inclisiran, 1 mg
J1551 — Injection, immune globulin (cutaquig), 100 mg
J2356 — Injection, tezepelumab-ekko, 1 mg
J2779 — Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
J2998 — Injection, plasminogen, human-tvmh, 1 mg
J3299 — Injection, triamcinolone acetonide (xipere), 1 mg
J9331 — Injection, sirolimus protein-bound particles, 1 mg
J9332 — Injection, efgartigimod alfa-fcab, 2mg
Q4259 — Celera dual layer or celera dual membrane, per square centimeter (add-on, list separately in addition to primary procedure)
Q4260 — Signature apatch, per square centimeter (add-on, list separately in addition to primary procedure)
Q4261 — Tag, per square centimeter (add-on, list separately in addition to primary procedure)

Deleted effective July 1, 2022 (5)

C9090 — Injection, plasminogen, human-tvmh, 1 mg
C9091 — Injection, sirolimus protein-bound particles, 1 mg
C9092 — Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg
C9093 — Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg
G9678 — Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation agreement

Added effective October 1, 2022 (22)

A2014 — Omeza collagen matrix or omeza complete matrix, per 100 mg
A2015 — Phoenix wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)
A2016 — Permeaderm b, per square centimeter (add-on, list separately in addition to primary procedure)
A2017 — Permeaderm glove, each
A2018 — Permeaderm c, per square centimeter (add-on, list separately in addition to primary procedure)
A4596 — Cranial electrotherapy stimulation (ces) system supplies and accessories, per month
A9602 — Fluorodopa f-18, diagnostic, per millicurie
A9607 — Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie
A9800 — Gallium ga-68 gozetotide, diagnostic, (locametz), 1 millicurie
C1834 — Pressure sensor system, includes all components (e.g., introducer, sensor), intramuscular (implantable), excludes mobile (wireless) software application
C9101 — Injection, oliceridine, 0.1 mg
C9142 — Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
E0183 — Powered pressure reducing underlay/pad, alternating, with pump, includes heavy duty
J1302 — Injection, sutimlimab-jome, 10 mg
J1932 — Injection, lanreotide, (cipla), 1 mg
J2777 — Injection, faricimab-svoa, 0.1 mg
J9274 — Injection, tebentafusp-tebn, 1 microgram
J9298 — Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
Q2056 — Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q5125 — Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
T1032 — Services performed by a doula birth worker, per 15 minutes
T1033 — Services performed by a doula birth worker, per diem

Deleted effective October 1, 2022 (5)

C9094 — Inj, sutimlimab-jome, 10 mg
C9095 — Inj, tebentafusp-tebn, 1 mcg
C9096 — Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
C9097 — Inj, faricimab-svoa, 0.1 mg
C9098 — Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Source: CMS HCPCS Level II alpha-numeric file (add and termination dates).

Source data

Source organization: CMS
Source release: HCPCS Level II October 2026 alpha-numeric file
Source file: october-2026-alpha-numeric-hcpcs-file.zip
File checksum (SHA-256): c25240c63108756d4ba6c0ea785c517117d83bfed9526c51da8acf123de1feb6
Data read date: Data not available in the current MedCoder release record.
Effective date: CMS effective dates within 2022
Release type: Quarterly (January, April, July, October), with occasional mid-quarter additions
Methodology: Each code's add date and termination date are read from the alpha-numeric file. A deletion is dated the first day the code is no longer valid, the day after its termination date. Description revisions are not recorded as changes.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

All releases in the Change Ledger